Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Registration Number
- NCT00184561
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in Asia. This is a clinical trial investigating the effectiveness of using Biphasic Insulin Aspart 70/30 in two different treatment regiments for 6 months in subjects with type 2 diabetes, not well controlled on their current oral anti-diabetic drug therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 321
Inclusion Criteria
- Type 2 diabetes
- HbA1C = 7.5%
- Insulin naïve
- Current treatment by Oral Anti-diabetic Drugs
Exclusion Criteria
- Severe medical conditions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in HbA1c After 24 weeks of treatment
- Secondary Outcome Measures
Name Time Method Hypoglycaemic episodes Weight change 2-hour postprandial blood glucose after 24 weeks of treatment. Adverse events Fasting blood glucose
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇨🇳Tianjin, Tianjin, China